

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO. FILING DATE		LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/036,421	01/07/2002		Kunio Okada	8010-1001 4679			
466	7590	05/03/2004		EXAM	EXAMINER		
YOUNG &	THOMP	SON	BECKER, DREW E				
		REET 2ND FLOOR		ART UNIT	PAPER NUMBER		
ARLINGTON, VA 22202				1761			

DATE MAILED: 05/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

					#>				
		Applicatio	n No.	Applicant(s)	70				
Office Action Summary		10/036,42	1	OKADA ET AL.					
		Examiner		Art Unit					
		Drew E Be		1761					
Period fo	The MAILING DATE of this communication Reply	ion appears on the	cover sheet with the o	correspondence add	dress				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status			·						
1)	Responsive to communication(s) filed or	n <i>02 March 2004</i> .							
	•	This action is not action is not action.	on-final.						
3)	,								
Disposit	ion of Claims								
5)□ 6)⊠ 7)□	4) Claim(s) 1-9 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.  5) Claim(s) is/are allowed.  6) Claim(s) 1-9 is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) are subject to restriction and/or election requirement.								
Applicat	ion Papers								
9)[	The specification is objected to by the Ex	kaminer.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority (	under 35 U.S.C. § 119								
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>									
Attachmer	nt(s)								
	ce of References Cited (PTO-892)		4) Interview Summary						
3) 🛛 Infor	ce of Draftsperson's Patent Drawing Review (PTO-5 mation Disclosure Statement(s) (PTO-1449 or PTO er No(s)/Mail Date <u>7/14/03</u> .		Paper No(s)/Mail D 5) Notice of Informal F 6) Other:		)-152)				

Application/Control Number: 10/036,421

Art Unit: 1761

#### **DETAILED ACTION**

#### Election/Restrictions

Claims 10-12 are withdrawn from further consideration pursuant to 37 CFR
 1.142(b) as being drawn to a nonelected group, there being no allowable generic or linking claim.

## Specification

2. The abstract of the disclosure is objected to because it has two separate paragraphs. Correction is required. See MPEP § 608.01(b).

## Claim Objections

3. Claims 4-9 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n).

# Claim Rejections - 35 USC § 112

- 4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

  The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 5. Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Page 3

Application/Control Number: 10/036,421

Art Unit: 1761

6. Claim 1 recites "(B) at least one substance selected from (a) at least one compound selected from... and (b) at least one substance selected from...". It is not clear whether the emulsion requires both (a) and (b), or simply one of them.

7. Claim 4 recites "L-arginine,... L-arginine L-glutamate". It is not clear whether L-arginine is being claimed twice, or not.

## Claim Rejections - 35 USC § 102

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

9. Claims 1-3 and 5-9 are rejected under 35 U.S.C. 102(e) as being anticipated by Euber [Pat. No. 6,077,558].

Euber teaches an emulsion comprising fats and oils (column 3, line 11), monoglycerides (column 4, line 19), proteins (column 2, line 47), amino acids (column 2, line 49), carageenan as a stabilizer (column 4, line 15), alkali salts such as sodium citrate (column 11, line 40), 0.9 parts monoglyceride per 100 parts oil (column 6, Table 1), 66.8 parts protein per 100 parts oil (column 6, Table 1), 1.3 parts amino acid per 100 parts oil (column 6, Table 1), 2.9 parts carageenan per 100 parts oil (column 6, Table 1), 4.8

Application/Control Number: 10/036,421

Art Unit: 1761

parts alkali salts per 100 parts oil (column 6, Table 1), and 33.3% solids (column 6,

Table 1).

## Claim Rejections - 35 USC § 103

- 10. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 11. Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Euber in view of Inoue et al [Pat. No. 5,972,367].

Euber teaches the above mentioned components. Euber does not recite L-arginine, L-lysine, L-histidine, L-proline, L-glutamate, or salts thereof. Inoue et al teach an emulsion comprising L-lysine, L-arginine, L-histidine, and L-proline (column 3, lines 40-50). It would have been obvious to one of ordinary skill in the art to incorporate the specific amino acids of Inoue et al into the invention of Euber since both are directed to emulsions, since Euber already required an amino acid mixture (column 6, line 39), and since these amino acids were commonly used in emulsions as shown by Inoue et al (column 3, lines 40-50).

12. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Translations of JP 59-162853, JP 59-23777, JP 63-126470, JP

Application/Control Number: 10/036,421

Art Unit: 1761

57-21969, JP 2000-125760 have been provided. Freck et al [Pat. No. 3,900,573] and Lamar III et al [Pat. No. 3,950,547] teach emulsions.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Drew E Becker whose telephone number is 571-272-1396. The examiner can normally be reached on Mon.-Thur. 8am-5pm and every other Fri. 8am-4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Milton Cano can be reached on 571-272-1398. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Drew E Becker Primary Examiner Art Unit 1761

4-29-04